首页> 外文OA文献 >Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma
【2h】

Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma

机译:肝细胞癌患者肝移植12年,单中心经验后肿瘤复发的预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Factors affecting outcomes after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) have been extensively studied, but some of them have only recently been discovered or reassessed. Methods. We analyzed classical and more recently emerging variables with a hypothetical impact on recurrence-free survival (RFS) in a single-center series of 283 patients transplanted for HCC between 1997 and 2009. Results. Five-year patient survival and RFS were 75% and 86%, respectively. Thirty-four (12%) patients had HCC recurrence. Elevated preoperative alpha-fetoprotein (AFP) levels, preoperative treatments of HCC, unfulfilled Milan and up-to-seven criteria at final histology, poor tumor differentiation, and tumor microvascular invasion negatively affected RFS by univariate analysis. Milan and up-to-seven criteria applied preoperatively, and the use of m-TOR inhibitors did not reach statistical significance. Cox's proportional hazard model showed that only elevated AFP levels (Odds Ratio = 2.88; 95% C.I. = 1.43–5.80; P = .003), preoperative tumor treatments (Odds Ratio = 4.84; 95% C.I. = 1.42–16.42; P = .01), and microvascular invasion (Odds Ratio = 4.82; 95% C.I. = 1.87–12.41; P = .001) were predictors of lower RFS. Conclusions. Biological aggressiveness and preoperative tumor treatment, rather than traditional and expanded dimensional criteria, conditioned the outcomes in patients transplanted for HCC.
机译:背景。已经广泛研究了影响原位肝移植(OLT)后肝细胞癌(HCC)结局的因素,但其中一些只是最近才被发现或重新评估。方法。我们分析了1997年至2009年间单中心研究的283例HCC移植患者的无复发生存(RFS)假设影响的经典变量和最近出现的变量。结果。五年患者生存率和RFS分别为75%和86%。三十四(12%)例HCC复发。术前α-甲胎蛋白(AFP)水平升高,术前HCC治疗,未完成的米兰检查和最终组织学标准达到七个标准,差的肿瘤分化和肿瘤微血管浸润通过单因素分析对RFS产生了负面影响。术前采用米兰和多达7个标准,并且m-TOR抑制剂的使用未达到统计学意义。 Cox的比例风险模型显示,术前肿瘤治疗仅提高AFP水平(几率= 2.88; 95%CI = 1.43–5.80; P = .003),赔率= 4.84; 95%CI = 1.42–16.42; P =。 01)和微血管浸润(几率= 4.82; 95%CI = 1.87–12.41; P = .001)是RFS降低的预测因素。结论。生物攻击性和术前肿瘤治疗,而不是传统的和扩大的尺寸标准,决定了肝癌移植患者的结局。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号